HFE Genotype and Endurance Performance in Competitive Male Athletes.
Journal
Medicine and science in sports and exercise
ISSN: 1530-0315
Titre abrégé: Med Sci Sports Exerc
Pays: United States
ID NLM: 8005433
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
pubmed:
13
1
2021
medline:
9
9
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
Hereditary hemochromatosis can cause individuals to absorb too much iron from their diet. Higher tissue iron content, below the threshold of toxicity, may enhance oxygen carrying capacity and offer a competitive advantage. Single nucleotide polymorphisms (SNP) in the homeostatic iron regulator (HFE) gene have been shown to modify iron metabolism and can be used to predict an individual's risk of hemochromatosis. Several studies have shown that HFE genotypes are associated with elite endurance athlete status; however, no studies have examined whether HFE genotypes are associated with endurance performance. The objectives of this study were to determine whether there was an association between HFE risk genotypes (rs1800562 and rs1799945) and endurance performance in a 10-km cycling time trial as well as maximal oxygen uptake (V˙O2peak), an indicator of aerobic capacity. Competitive male athletes (n = 100; age = 25 ± 4 yr) completed a 10-km cycling time trial. DNA was isolated from saliva and genotyped for the rs1800562 (C282Y) and rs1799945 (H63D) SNP in HFE. Athletes were classified as low risk (n = 88) or medium/high risk (n = 11) based on their HFE genotype for both SNP using an algorithm. ANCOVA was conducted to compare outcome variables between both groups. Individuals with the medium- or high-risk genotype were ~8% (1.3 min) faster than those with the low-risk genotype (17.0 ± 0.8 vs 18.3 ± 0.3 min, P = 0.05). V˙O2peak was ~17% (7.9 mL·kg-1⋅min-1) higher in individuals with the medium- or high-risk genotype compared with those with the low-risk genotype (54.6 ± 3.2 vs 46.7 ± 1.0 mL·kg-1⋅min-1, P = 0.003). Our findings show that HFE risk genotypes are associated with improved endurance performance and increased V˙O2peak in male athletes.
Identifiants
pubmed: 33433155
doi: 10.1249/MSS.0000000000002595
pii: 00005768-202107000-00008
doi:
Substances chimiques
HFE protein, human
0
Hemochromatosis Protein
0
Banques de données
ClinicalTrials.gov
['NCT02109783']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1385-1390Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2020 by the American College of Sports Medicine.
Références
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med . 2009;361(25):2436–48.
Hollerer I, Bachmann A, Muckenthaler MU. Pathophysiological consequences and benefits of HFE mutations: 20 years of research. Haematologica . 2017;102(5):809–17.
McKay AKA, Pyne DB, Burke LM, Peeling P. Iron metabolism: interactions with energy and carbohydrate availability. Nutrients . 2020;12(12):3692.
Porto G, Brissot P, Swinkels DW, et al. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet . 2016;24(4):479–95.
Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload–related disease in HFE hereditary hemochromatosis. N Engl J Med . 2008;358(3):221–30.
Hanson EH. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemiol . 2001;154(3):193–206.
Guest NS, Horne J, Vanderhout SM, El-Sohemy A. Sport nutrigenomics: personalized nutrition for athletic performance. Front Nutr . 2019;6:8.
Hermine O, Dine G, Genty V, et al. Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. Biochimie . 2015;119:1–5.
Chicharro JL. Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes. Br J Sports Med . 2004;38(4):418–21.
Brutsaert TD, Hernandez-Cordero S, Rivera J, Viola T, Hughes G, Haas JD. Iron supplementation improves progressive fatigue resistance during dynamic knee extensor exercise in iron-depleted, nonanemic women. Am J Clin Nutr . 2003;77(2):441–8.
Grealy R, Herruer J, Smith CLE, Hiller D, Haseler LJ, Griffiths LR. Evaluation of a 7-gene genetic profile for athletic endurance phenotype in ironman championship triathletes. Roemer K, editor. Plos one . 2015;10(12):e0145171.
Guest N, Corey P, Vescovi J, El-Sohemy A. Caffeine, CYP1A2 genotype, and endurance performance in athletes. Med Sci Sports Exerc . 2018;50(8, 8):1570.
Josse AR, Da Costa LA, Campos H, El-Sohemy A. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. Am J Clin Nutr . 2012;96(3):665–71.
Semenova EA, Miyamoto-Mikami E, Akimov EB, et al. The association of HFE gene H63D polymorphism with endurance athlete status and aerobic capacity: novel findings and a meta-analysis. Eur J Appl Physiol . 2020;120(3):665–73.
Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci Off J Isfahan Univ Med Sci . 2014;19(2):164–74.
Volpe SL. Iron and athletic performance. ACSMs Health Fit J . 2010;14(5):31–3.
Marengo-Rowe AJ. Structure–function relations of human hemoglobins. Bayl Univ Med Cent Proc . 2006;19(3):239–45.
Mairbäurl H. Red blood cells in sports: effects of exercise and training on oxygen supply by red blood cells. Front Physiol . 2013;4–332.
Böning D, Schweigart U, Tibes U, Hemmer B. Influences of exercise and endurance training on the oxygen dissociation curve of blood under in vivo and in vitro conditions. Eur J Appl Physiol . 1975;34(1):1–10.
Braumann KM, Boning D, Trost F. Bohr effect and slope of the oxygen dissociation curve after physical training. J Appl Physiol . 1982;52(6):1524–9.
Schmidt W, Prommer N. Impact of alterations in total hemoglobin mass on V˙O 2max . Exerc Sport Sci Rev . 2010;38(2):68–75.
Bauer C. Antagonistic influence of CO 2 and 2,3 diphosphoglycerate on the Bohr effect of human haemoglobin. Life Sci . 1969;8(20):1041–6.
Berglund B, Hemmingson P. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers. Int J Sports Med . 1987;8(3):231–3.
Calbet JAL, Lundby C, Koskolou M, Boushel R. Importance of hemoglobin concentration to exercise: acute manipulations. Respir Physiol Neurobiol . 2006;151(2–3):132–40.
Fallon KE. Screening for haematological and iron-related abnormalities in elite athletes-analysis of 576 cases. J Sci Med Sport . 2008;11(3):329–36.
Malczewska J, Szczepańska B, Stupnicki R, Sendecki W. The assessment of frequency of iron deficiency in athletes from the transferrin receptor-ferritin index. Int J Sport Nutr Exerc Metab . 2001;11(1):42–52.
Parks RB, Hetzel SJ, Brooks MA. Iron deficiency and anemia among collegiate athletes: a retrospective chart review. Med Sci Sports Exerc . 2017;49(8):1711–5.
Sekulic D, Tahiraj E, Maric D, Olujic D, Bianco A, Zaletel P. What drives athletes toward dietary supplement use: objective knowledge or self-perceived competence? Cross-sectional analysis of professional team-sport players from Southeastern Europe during the competitive season. J Int Soc Sports Nutr . 2019;16(1):25.
Rietjens GJ, Kuipers H, Hartgens F, Keizer HA. Red blood cell profile of elite Olympic distance triathletes. A three-year follow-up. Int J Sports Med . 2002;23(6):391–6.
Lukaski HC. Vitamin and mineral status: effects on physical performance. Nutr Burbank Los Angel Cty Calif . 2004;20(7–8):632–44.
Sinclair LM, Hinton PS. Prevalence of iron deficiency with and without anemia in recreationally active men and women. J Am Diet Assoc . 2005;105(6):975–8.
Sim M, Garvican-Lewis LA, Cox GR, et al. Iron considerations for the athlete: a narrative review. Eur J Appl Physiol . 2019;119(7):1463–78.
Buratti P, Gammella E, Rybinska I, Cairo G, Recalcati S. Recent advances in iron metabolism: relevance for health, exercise, and performance. Med Sci Sports Exerc . 2015;47(8):1596–604.
Magnusson B, Hallberg L, Rossander L, Swolin B. Iron metabolism and “sports anemia.” II. A hematological comparison of elite runners and control subjects. Acta Med Scand . 1984;216(2):157–64.
Watts E. Athletes’ anaemia. A review of possible causes and guidelines on investigation. Br J Sports Med . 1989;23(2):81–3.
Recalcati S, Minotti G, Cairo G. Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal . 2010;13(10):1593–616.
Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell . 2016;167(5):1415–1429.e19.
Mast AE, Lee T-H, Schlumpf KS, et al. The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*: HFE mutations in blood donors. Br J Haematol . 2012;156(3):388–401.
Luszczyk M, Kaczorowska-Hac B, Milosz E, et al. Reduction of skeletal muscle power in adolescent males carrying H63D mutation in the HFE gene. Biomed Res Int . 2017;2017:1–7.